Researchers who looked at findings from 10 studies found rapid infusions of infliximab did not raise risks among patients with inflammatory bowel disease and other other conditions, compared with standard infusions. In addition, University of Michigan researchers reported that nine of the studies, seven of which were focused on IBD patients, suggested a reduced reaction risk when comparing rapid and standard infusion.

Related Summaries